Not one specific thing. Just have to read the notes and determine if there are serious questions or issues the FDA poses. If not then people will see that the meeting will go smoothly. If there are hangups on issue of safety, then it may pose a tougher challenge for DVAX. It is all subjective that is why each investor reads the notes to determine for themselves.
Market Data 
Markets 
AI
